Live Breaking News & Updates on Centre For Drug Development
Stay updated with breaking news from Centre for drug development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cancer Research UK and Guardant collaborate to advance cancer detection and treatment pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Cancer Research UK and KWF Dutch Cancer Society partner for drug development pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody. The Phase 1/2a clinical trial in the United Kingdom is being sponsored and managed by CRUK's Centre for Drug Development and led by Chief Investigator, Professor Johann De Bono at the Royal Marsden Hospital and The Institute of Cancer Research, London. The Phase 1a stage of the trial is currently enrolling multiple solid tumor cancer patients resistant to approved therapies, and is aimed at identifying a recommended Phase 2 dose for further evaluation. "We decided to exercise the ....
SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody. The Phase 1/2a clinical trial in the United Kingdom is being sponsored and managed by CRUK's Centre for Drug Development and led by Chief Investigator, Professor Johann De Bono at the Royal Marsden Hospital and The Institute of Cancer Research, London. The Phase 1a stage of the trial is currently enrolling multiple solid tumor cancer patients resistant to approved therapies, and is aimed at identifying a recommended Phase 2 dose for further evaluation. "We decided to exercise the ....